Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Nanoliposomal Irinotecan (Onivyde) for Metastatic Pancreatic Cancer
(Pending Submission as of September 23, 2016)

Lenvatinib (Lenvima) for Differentiated Thyroid Cancer
(Final Recommendation posted as of September 20, 2016)

Ceritinib (Zykadia) for Non-Small Cell Lung Cancer (Resubmission)
(Pending Submission as of September 14, 2016)

Brentuximab vedotin (Adcetris) for Hodgkin Lymphoma (post-ASCT consolidation)
(Review Withdrawn as of September 9, 2016)

Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed/refractory)
(Open for Input on Submission until September 23, 2016)

Alectinib (TBD) for Non-Small Cell Lung Cancer
(Pending Submission as of August 31, 2016)

Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma
(Notification to Implement Issued as of September 19, 2016)

Find a Drug Review